Nasopharyngeal carcinoma, particularly the undifferentiated type (UCNT), is a rare malignancy with a variable incidence. It is a distinct entity from other head and neck tumors due to its specific multifactorial etiology and the contribution of Epstein-Barr virus (EBV) in its oncogenesis. Radiotherapy remains the reference treatment. The objective of our work was to define the place of neoadjuvant chemotherapy in the treatment of locally advanced non-metastatic nasopharyngeal cancer.